SERPINE1 and COVID-19: Indeed, PAI-1 has been identified as a potential target in COVID-19 and its antagonists, such as statins, are currently in clinical trials (NCT04634799) (NCT04472611) (Bouarab et al., 2021; Kellici et al., 2021; Figure 2).